Vaccibody.com | Lisa Gerner
7
archive,author,author-lisa,author-7,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-16.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.5,vc_responsive

Vaccibody AS, a clinical stage immuno-oncology company, announced today that it has entered into a collaboration with Roche to explore a combination of Vaccibody’s VB10.16 and the PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced cervical cancer. Vaccibody expects to start a phase II...

Vaccibody AS today announced positive 6-months interim results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...

Vaccibody AS, a clinical-stage company focused on developing cancer vaccines to target solid tumors, today announces clinical data demonstrating vaccine-induced killer T cell responses (CD8+) in patients in their clinical program to treat precancerous cervical intraepithelial neoplasia (CIN) 2/3 lesions (VB C-01). President and Chief...